<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11540">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832506</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200095-003</org_study_id>
    <nct_id>NCT01832506</nct_id>
  </id_info>
  <brief_title>A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors</brief_title>
  <official_title>A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Japanese multicenter, open-label, Phase 1 study to evaluate safety and efficacy of
      MSC2156119J in subjects with malignant solid tumor which is refractory to standard therapy
      or to which no effective standard therapy is applicable.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects experiencing Dose Limiting Toxicity</measure>
    <time_frame>up to Day 21 of Cycle 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Treatment-emergent adverse events</measure>
    <time_frame>Baseline up to Day 30 after the last day of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Cmax, tmax, t1/2, AUC, CL/f, V(z)/f, V(ss)/f of MSC2156119J post-administration</measure>
    <time_frame>Day 1, 2, 3, 8, 14, 15 and 17 of Cycle 1, and Day 1 and 14 of Cycle 2, and Day 1 of Cycle 3 and 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic markers levels in blood and tumor tissue</measure>
    <time_frame>Day 1, 2, 3, 8, 14, 15 and 17 of Cycle 1, and Day 1 and 14 of Cycle 2, and Day 1 of Cycle 3 and 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacodynamic and circulating biomarkers such as hepatocellular growth factor will be measured in blood and proximal Pharmacodynamic biomarkers such as total c-Met or phospho-c-Met will be measured in tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Clinical Benefit</measure>
    <time_frame>Baseline until the date of first documented progression, up to Day 30 after the last day of study treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with Clinical Benefit is defined as subjects with Complete response (CR) or Partial response (PR), at any time point or stable disease at week 12 or later, based on tumor assessment as determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>Baseline until first observation of progressive disease, or death  within  12 weeks  of  the  last  tumor  assessment or first administration of MSC2156119J, up to Day 30 after the last day of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between c-Met over-expression, amplification and mutation in tumor tissue and  hepatocellular growth factor (HGF)  levels in  plasma, and tumor response to MSC2156119J treatment</measure>
    <time_frame>Day 1 of Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MSC2156119J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC2156119J</intervention_name>
    <description>MSC2156119J will be administered in the assigned doses in combinations of 15 milligram (mg) and/or 100 mg capsules orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.</description>
    <arm_group_label>MSC2156119J</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject with a histologically or cytologically confirmed diagnosis of malignant
             solid tumor which is refractory to standard therapy or to which no effective standard
             therapy is applicable

          -  An archived tumor tissue is available or biopsy of tumor tissues can be newly
             performed

          -  A Japanese male or female, age greater than or equal to 20 years

          -  A subject who has read the Subject Information Sheet and understood the details of
             this clinical trial, and is willing and able to give his/her informed consent.

          -  A female of child-bearing potential must have a negative blood pregnancy test result
             at her screening period. A female subject of child-bearing potential must be willing
             to avoid pregnancy by using an adequate method of contraception Life expectancy is at
             least 3 months

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  Known Human immunodeficiency virus (HIV) positivity, active hepatitis C, or active
             hepatitis B

          -  Presence of liver fibrosis or liver cirrhosis that has been histologically diagnosed

          -  Signs or symptoms that suggest transmissible spongiform encephalopathy

          -  Received major surgery within 6 weeks before Day 1 in Cycle 1

          -  Known drug abuse or alcohol abuse

          -  Known hypersensitivity to any of the trial treatment ingredients

          -  Hematological test abnormalities

          -  Renal impairment as defined in the protocol

          -  Liver dysfunction as defined in the protocol

          -  History or presence of central nervous system metastasis

          -  History or presence of disease or condition that may hamper compliance or absorption
             of the investigational medicinal product (IMP) due to difficulty in swallowing or
             absorption

          -  Poor performance status of Eastern Cooperative Oncology Group Performance status
             (ECOG PS) greater than or equal to 2

          -  Received any anti-cancer therapy days Received extensive prior radiotherapy that
             irradiates more than 30 percent of bone marrow

          -  Received any radiotherapy within 4 weeks before Day 1 in Cycle 1

          -  Pregnancy and lactation period

          -  History of receiving treatment with any c-Met signaling pathway inhibitor

          -  Participation in another interventional clinical trial within the past 30 days from
             Day 1 in Cycle 1

          -  Other significant disease that in the Investigator's opinion would exclude the
             subject from the trial

          -  Legal incapacity or limited legal capacity

          -  Other exclusion criteria apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kotaro Funato</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd., Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merck.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>April 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>MSC2156119J</keyword>
  <keyword>c-Met inhibitor</keyword>
  <keyword>Japanese</keyword>
  <keyword>Phase 1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
